SCHEMBL1203528

SCHEMBL1203528

O=C(Nc1ccccc1)c1cnc2ccc(OCc3ccccc3)nn12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SGMS2 Q8NHU3 2/20 0.47
▸ KIT P10721 1/20 0.44
▸ DDR1 Q08345 1/20 0.44
▸ DDR2 Q16832 1/20 0.44
▸ RAB9A P51151 4/20 0.44
▸ NPC1 O15118 4/20 0.44
▸ MEN1 O00255 4/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ RXFP1 Q9HBX9 1/20 0.44
▸ PABPC1 P11940 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ CXCR2 P25025 2/20 0.41
▸ CXCR1 P25024 1/20 0.41
▸ JAK3 P52333 1/20 0.41
▸ PPIA P62937 1/20 0.40
▸ CASP3 P42574 1/20 0.40
▸ SENP7 Q9BQF6 1/20 0.40
▸ PTGER1 P34995 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1202432 0.83 KDR (0.52) KITRAB9ANPC1MEN1KMT2A
SCHEMBL1203719 0.80 KIT (0.45) KITDDR1DDR2RAB9ANPC1
SCHEMBL1202452 0.79 FYN (0.49) MEN1KMT2ASMN1; SMN2CXCR2
SCHEMBL1203470 0.78 KCNQ3 (0.46) KITDDR1DDR2RAB9ANPC1
SCHEMBL1202745 0.77 MKNK1 (0.56) KITDDR1DDR2RAB9ANPC1
SCHEMBL1203606 0.77 FYN (0.59) —
SCHEMBL1202920 0.76 PIM1 (0.53) KITDDR1DDR2
SCHEMBL1203700 0.76 NTRK1 (0.54) KITDDR1DDR2
SCHEMBL1203484 0.75 DDR2 (0.44) KITDDR1DDR2RAB9ANPC1
SCHEMBL6927893 0.74 CXCR2 (0.68) SGMS2RAB9ANPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2011-02-24 — — US disclosed
EP-2217601-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) 2010-08-18 — — EP disclosed
WO-2009060197-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2009-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors PIM1, PIM3, PIM2 SGMS2 4564/4885KIT 459/4885DDR1 2158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback